WLF v. Crawford? Off-Label Dissemination Dissent May Trigger Second Suit
This article was originally published in The Gray Sheet
FDA's recent request for comments on labeling and promotional speech regulation, while an "encouraging sign," may be an attempt to stave off further litigation, Washington Legal Foundation Chief Counsel Richard Samp asserted May 30
You may also be interested in...
FDA's request for comments on First Amendment issues creates a forum for stakeholders to submit comments on FDA's policy regarding off-label claims
Dissemination of journal reprints representing off-label use of a device or drug will not by themselves trigger FDA enforcement action against a manufacturer, according to the agency
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.